Brokerage firm Nuvama Research has reiterated its ‘BUY’ rating for Jubilant Pharmova, setting a 12-month share price target of Rs 1,140 despite recent operational hurdles. The announcement comes as investors weigh the company’s robust Contract Development and Manufacturing Organization (CDMO) performance against ongoing challenges at its Montreal manufacturing facility.
Context: Balancing Growth and Operational Constraints
Jubilant Pharmova recently reported a 21 percent decline in consolidated net profit, which fell to Rs 119.3 crore for the March quarter, compared to Rs 151.3 crore in the same period last year. The decline was largely attributed to exceptional items that impacted the bottom line, despite a healthy increase in total revenue from operations to Rs 2,290 crore from Rs 1,928.8 crore a year earlier.
The company’s Montreal facility has been a focal point for analysts, as regulatory and operational challenges there have necessitated a downward revision of near-term earnings estimates. However, market experts suggest that these issues are transient and do not negate the fundamental strength of the company’s core business segments.
The CDMO Engine Driving Momentum
The standout performer in the recent quarterly results was the CDMO-Sterile Injectables (CDMO-SI) business, which posted a significant 57 percent growth rate. This division is increasingly viewed as the primary engine for future value creation for the pharmaceutical firm.
Nuvama’s report highlights that the CDMO pipeline is robust, currently featuring more than 10 molecules. Notably, this includes a large commercial oncology product, which analysts believe will provide long-term revenue stability and margin expansion as it transitions into full-scale commercialization.
Financial Outlook and Shareholder Value
With the stock recently closing at Rs 1,006, the new price target of Rs 1,140 implies a potential upside of approximately 13.3 percent over the next year. To bolster investor confidence, the company’s board has recommended a final dividend of Rs 5 per equity share for the financial year ending March 31, 2026.
Industry analysts emphasize that while the Montreal situation requires monitoring, the broader shift toward global pharmaceutical outsourcing continues to favor companies with established sterile injectable capabilities. The ability of Jubilant Pharmova to scale its high-value oncology portfolio will likely determine its ability to meet or exceed these ambitious price targets.
Implications for the Sector
For investors, the recent analyst sentiment underscores the importance of looking beyond immediate quarterly volatility when evaluating CDMO-focused pharmaceutical stocks. The industry trend suggests that specialized manufacturing capacity remains in high demand, particularly for complex oncology treatments.
Looking ahead, market participants should monitor updates regarding the operational status of the Montreal facility, as any resolution or improvement in efficiency there could act as a significant catalyst for the stock. Furthermore, progress reports on the integration of the new oncology pipeline molecules will be critical benchmarks to watch in upcoming quarterly disclosures.
